Cleveland clinic peripheral arterial disease

A structured exercise rehabilitation program is one of the most effective strategies to improve claudication symptoms. Maintenance of such a program should be considered indefinitely or the benefit may eventually be lost. The limitations of exercise rehabilitation programs are cost, lack of availability, and insurance coverage. Cilostazol Pletal , is a reversible phosphodiesterase inhibitor that inhibits platelet aggregation, thrombin formation, and vascular smooth muscle proliferation, promotes vasodilation, and increases HDL and lowers TG levels.

In randomized placebo-controlled trials, cilostazol has been found to be superior to placebo and pentoxifylline Trental , which is also an FDA-approved medication for relieving claudication and improving pain-free and maximal treadmill walking distance, community-based ambulation, and quality of life.

Most of these side effects, however, are short lived and rarely require discontinuation of the medication. Given the increased incidence of sudden cardiac death with other phosphodiesterase inhibitors e. Pentoxifylline is a methylxanthine derivative that decreases blood viscosity and has hemorheologic improves erythrocyte and leukocyte deformability , anti-inflammatory, and antiproliferative effects.

Since its approval for intermittent claudication in , two meta-analyses and two systematic reviews have concluded that its effect on improving walking capacity is small, if any. Thus, it has lost its status as a widely used medication for this indication. At present, the absolute indications for lower extremity revascularization are acute limb ischemia, critical limb ischemia usually manifested as rest pain, nonhealing lower extremity ulcers , and lifestyle, vocational, or economically limiting claudication.

Box 6 lists the accepted indications for revascularization in patients presenting with intermittent claudication. Box 7 shows factors that increase the risk of limb loss in patients with critical limb ischemia, and Table 4 lists the clinical categories of acute limb ischemia. Circulation ;ee Reprinted with permission from Katzen BT: Clinical diagnosis and prognosis of acute limb ischemia.

Short stenotic or occlusive lesions can generally be successfully treated percutaneously, whereas long lesions usually require surgical treatment. Percutaneous angioplasty carries a lower risk compared with surgical revascularization and can be performed on an outpatient basis.

Although primary stent placement in the iliac arteries appears to improve long-term patency rates, stent placement in the femoropopliteal area is reserved for special cases, such as suboptimal angioplasty result and flow-limiting dissection.

Catheter-directed thrombolytic therapy is an accepted initial treatment strategy for acute limb ischemia. Thrombus resolution allows for better visualization of underlying atherosclerotic lesions and offers an opportunity for simultaneous treatment with percutaneous angioplasty. Careful patient selection and excluding patients with high bleeding risk are necessary to minimize hemorrhagic complications.

Surgery is advocated for many patients presenting with acute or critical limb ischemia. Occasionally, it is used for individuals with lifestyle-limiting claudication. Endarterectomy and bypass grafting are the two most commonly used surgical techniques. Generally, endarterectomy is feasible and offers an excellent success rate when used for proximal arterial segments aorta, iliac, common femoral or profunda arteries and bypass grafting is preferable for distal, long, or diffuse disease.

Use of perioperative beta blockers is indicated because they significantly reduce the risk of cardiovascular complications including MI and death. PAD is a prevalent systemic atherosclerotic disease with associated high cardiovascular morbidity and mortality. Despite the fact that PAD can be noninvasively and accurately diagnosed with the ABI, it often remains underdiagnosed and undertreated. Health care providers must make every effort to detect the disease at an early stage, assess associated risk factors, and provide proper long-term care.

Aggressive management of atherosclerotic risk factors, a structured exercise program, use of antiplatelet agents and, when indicated, percutaneous or surgical revascularization are the keys for successful management. Our application website is closed until further notice. We are currently closed for the remainder of to new and prospective students due to the COVID pandemic. Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website.

These cookies do not store any personal information. Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

Enter the username or e-mail you used in your profile. A password reset link will be sent to you by email. The lecture below can be accessed on the Disease Management section of the Cleveland Clinic, under Allergy and Immunology to go to this link and see others in the series, please click here Peripheral Arterial Disease Amjad Al Mahameed Published: January Definition Peripheral arterial disease PAD , cerebrovascular disease, and coronary artery disease CAD are the three major syndromes of atherothrombosis.

Figure 2: Click to Enlarge. In symptomatic patients: Most have atypical exertional leg pain. Minority progress to rest pain or ischemic ulcers critical limb ischemia.

Figure 3: Click to Enlarge. Optimize diabetes management. Treat claudication with cilostazol. Box 6: Indications for Revascularization in Intermittent Claudication Before a patient with intermittent claudication is offered the option of any invasive revascularization therapy, endovascular or surgical, the following considerations must be taken into account: Predicted or observed lack of adequate response to exercise therapy and claudication pharmacotherapies Presence of a severe disability, with the patient being unable to perform normal work or having very serious impairments of other activities important to the patient Absence of other disease that would limit exercise even if the claudication was improved e.

Box 7: Factors that Increase Risk of Limb Loss in Patients with Critical Limb Ischemia Factors that reduce blood flow to the microvascular bed: Diabetes Severe renal failure Severely decreased cardiac output severe heart failure or shock Vasospastic diseases or concomitant conditions e. References American Heart Association. Heart Disease and Stroke Statistics— Prevalence of and risk factors for peripheral arterial disease in the United States.

The prevalence of peripheral arterial disease in a defined population. The epidemiology of peripheral arterial disease: Importance of identifying the population at risk. Vasc Med. Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study.

Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. Atherosclerotic risk factors are less intensively treated in patients with peripheral arterial disease than in patients with coronary artery disease. J Gen Intern Med. Intermittent claudication. A risk profile from The Framingham Heart Study. Lower extremity arterial disease in elderly subjects with systolic hypertension. J Clin Epidemiol. The role of tobacco cessation, antiplatelet and lipid-lowering therapies in the treatment of peripheral arterial disease.

Cessation of smoking in patients with intermittent claudication. Effects on the risk of peripheral vascular complications, myocardial infarction and mortality.

Acta Med Scand. The measured effect of stopping smoking on intermittent claudication. Br J Surg. The influence of smoking on the level of lower limb amputation. Prosthet Orthot Int. Arteriosclerosis obliterans and associated risk factors in insulin-dependent and non—insulin-dependent diabetes.

Serum lipoproteins and hemostatic function in intermittent claudication. Arterioscler Thromb. Effect of diagnostic criteria on the prevalence of peripheral arterial disease. Leg symptoms commonly reported by men and women with lower extremity peripheral arterial disease: Associated clinical characteristics and functional impairment.

Quality of life and peripheral obliterative arteriopathy. Perspective for the future. Management of peripheral arterial disease PAD. J Vasc Surg. Risk factors and cardiovascular diseases associated with asymptomatic peripheral arterial occlusive disease.

Peripheral Arterial Occlusive Disease. Scand J Prim Health Care. Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population.

Int J Epidemiol. The ratio of ankle and arm arterial pressure as an independent predictor of mortality. The long-term prognostic value of the resting and postexercise ankle-brachial index. The peripheral vascular consequences of smoking. Ann Vasc Surg. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: A meta-analysis. Arch Intern Med. Treating tobacco use and dependence: An evidence-based clinical practice guideline for tobacco cessation.

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes UKPDS Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study 4S.

Am J Cardiol. National Cholesterol Education Program. Heart Protection Study Collaborative Group. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease.

The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease.

A meta-analysis of randomized controlled trials. Effect of beta blockers on incidence of new coronary events in older persons with prior myocardial infarction and symptomatic peripheral arterial disease. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease.

Eur Heart J. Cardiovascular risk prevention in peripheral artery disease. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. There is very strong evidence this dietary modification is effective in reducing hypertension, cardiovascular disease risk and cardiovascular disease progression.

This diet can improve life quality and expectancy if you have cardiovascular disease. Once again, as with the other diets noted above, this diet has not specifically been compared exclusively in those with PAD. This diet — especially when added to a low-fat diet — can reduce triglycerides and increase good cholesterol levels, both of which can benefit patients with cardiovascular disease.

These can also be recommended if you have PAD, and following this diet can result in reducing your overall cardiovascular risk. All of these diets provide various benefits, Zumpano says.

To choose a diet that is best for your specific needs, be sure to discuss with your doctor or a registered dietitian. The Ornish Spectrum diet and the Weil anti-inflammatory diet along with the Esselstyn diet utilize some combination of plant-based, low-fat and low-carbohydrate diets along with limitations of protein intake from meats, eggs and dairy. There is limited data to guide recommendations regarding these diets, but they do appear to provide benefit by incorporating principles behind proven diets.

However, little can be said about proof of their specific benefits. These diets use proven principles in the foods they recommend, and because the basics of these principles are proven to improve life quality and expectancy, the diets can be recommended if you have PAD.

However, these diets may prove much more challenging to adhere to than the others mentioned above, and there is limited clinical evidence they provide additional benefit. Reducing saturated and mono-unsaturated fats, restricting sodium and increasing fiber are key. Learn more about vaccine availability. Advertising Policy. You have successfully subscribed to our newsletter. Related Articles. How to Naturally Lower Your Cholesterol. What Are the Best Sources of Protein?